Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? (Q37588725)

21 August 2017

1 reference

title

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'? (English)

1 reference

21 August 2017

1 reference

John D Isaacs

3

0 references

author name string

Robert J Moots

series ordinal

1

1 reference

PubMed ID

19715449

21 August 2017

Andrew Jk Ostör

series ordinal

2

1 reference

PubMed ID

19715449

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

18

1 reference

21 August 2017

1687-1699

1 reference

21 August 2017

11

1 reference

The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register.

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Rheumatic diseases: the effects of inflammation on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Therapeutic strategies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Evolving concepts of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Role of interleukin-6 in the anemia of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Extra-articular manifestations and complications of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Lung disease in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Acute-phase proteins and other systemic responses to inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Clinical experience with inhibition of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

IL-6 in autoimmune disease and chronic inflammatory proliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

IL-6 transsignaling: the in vivo consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Stimulation of CRP secretion in HepG2 cells: Cooperative effect of dexamethasone and interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

IL-6-induced anaemia in rats: possible pathogenetic implications for anemia observed in chronic inflammations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Elevated plasma free fatty acid concentrations do not modify cardiac repolarization in patients treated by electrolyte-glucose-insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Acute-phase response factor, increased binding, and target gene transcription during liver regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728220903185939

10.1517/14728220903185939

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19715449